Gus R Rosania
Overview
Explore the profile of Gus R Rosania including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De la Rosa M, Patel D, McCann M, Stringer K, Rosania G
Sci Rep
. 2023 Dec;
13(1):22013.
PMID: 38086883
Adverse drug reactions (ADRs) are considered an inherent risk of medication use, and some ADRs have been associated with off-target drug interactions with mitochondria. Metabolites that reflect mitochondrial function may...
2.
LaLone V, Smith D, Diaz-Espinosa J, Rosania G
Adv Drug Deliv Rev
. 2023 Sep;
202:115107.
PMID: 37769851
Raman confocal microscopes have been used to visualize the distribution of small molecule drugs within different subcellular compartments. This visualization allows the discovery, characterization, and detailed analysis of the molecular...
3.
Willmer A, Diaz-Espinosa J, Zhou A, Stringer K, Rosania G
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765318
The antimycobacterial drug clofazimine (CFZ) is used as a single agent at high doses, to suppress the exaggerated inflammation associated with leprosy. Paradoxically, increasing doses of CFZ leads to bioaccumulation...
4.
Diaz-Espinosa J, Stringer K, Rosania G
Metabolites
. 2023 May;
13(5).
PMID: 37233713
Mitochondrial health declines with age, and older patients can demonstrate dysfunction in mitochondrial-rich tissues, such as cardiac and skeletal muscle. Aged mitochondria may make older adults more susceptible to adverse...
5.
Willmer A, Nie J, De la Rosa M, Wen W, Dunne S, Rosania G
J Control Release
. 2022 May;
347:620-631.
PMID: 35623493
Weakly basic small molecule drugs like clofazimine can be used as building blocks for endowing cells with unnatural structural and functional elements. Here, we describe how clofazimine represents a first-in-class...
6.
Willmer A, Dunne S, Swanson R, Almeida D, Ammerman N, Stringer K, et al.
Pharmaceutics
. 2022 Jan;
14(1).
PMID: 35056913
Clofazimine (CFZ) is a weakly basic, small-molecule antibiotic used for the treatment of mycobacterial infections including leprosy and multidrug-resistant tuberculosis. Upon prolonged oral administration, CFZ precipitates and accumulates within macrophages...
7.
Dunne S, Willmer A, Swanson R, Almeida D, Ammerman N, Stringer K, et al.
Pharmaceutics
. 2022 Jan;
14(1).
PMID: 35056910
Clofazimine (CFZ) is a poorly soluble, weakly basic, small molecule antibiotic clinically used to treat leprosy and is now in clinical trials as a treatment for multidrug resistant tuberculosis and...
8.
Silmore L, Willmer A, Capparelli E, Rosania G
Pharmacotherapy
. 2021 Feb;
41(4):405-420.
PMID: 33583102
Cannabidiol (CBD), a non-psychotropic phytocannabinoid from the Cannabis plant, is increasingly being pursued as a treatment for differing ailments. The bioavailability and pharmacokinetics of CBD are not well understood, and...
9.
McCann M, De la Rosa M, Rosania G, Stringer K
Metabolites
. 2021 Jan;
11(1).
PMID: 33466750
Biomarker discovery and implementation are at the forefront of the precision medicine movement. Modern advances in the field of metabolomics afford the opportunity to readily identify new metabolite biomarkers across...
10.
Tan J, Murashov M, Rosania G, Wang X
PLoS One
. 2019 Jul;
14(7):e0219655.
PMID: 31306463
Prostate cancer was the most common form and had the second highest death rate of male cancer in the United States in 2015. Current diagnosis techniques, such as prostate-specific antigen...